Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high 2 capacity to mediate membrane fusion 3 Health, Beijing Key Laboratory for Animal Models of Emerging and Re-emerging Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of